Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years
Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.
Authors
- Maria Mazzitelli (ORCID: https://orcid.org/0000-0003-0263-0703)
- Alessandra Coin (ORCID: https://orcid.org/0000-0003-1687-4493)
- Silvia Nozza
- Luca Bonaffini
- Bernard Fioretti (ORCID: https://orcid.org/0000-0002-9570-4195)
- Francesca Italiani
- A. De Vito
- Anna Spolti
- Giuseppe Bellelli (ORCID: https://orcid.org/0000-0001-5430-0947)
- Benedetto Maurizio Celesia (ORCID: https://orcid.org/0000-0002-6919-1955)
- Giancarlo Orofino (ORCID: https://orcid.org/0000-0003-3115-9674)
- Giuseppe Vittorio De Socio (ORCID: https://orcid.org/0000-0001-8774-4843)
- Domenico Azzolino (ORCID: https://orcid.org/0000-0002-4910-7373)
- Alessandra Marengoni (ORCID: https://orcid.org/0000-0002-4851-1825)
- A Cattelan
- Caterina Candela (ORCID: https://orcid.org/0000-0001-8163-3130)
- Silvia Pontiggia
- Lavinia Maria Alessandra Patetta
- S. Calza
- Giordano Madeddu (ORCID: https://orcid.org/0000-0001-6099-2273)
- Maria Vittoria Cossu (ORCID: https://orcid.org/0000-0002-6984-3028)
- Alessandro Lazzaro (ORCID: https://orcid.org/0000-0002-6297-9387)
- Stefania Piconi (ORCID: https://orcid.org/0000-0001-7058-1048)
- Jovana Milić
- Maria Grazia Maddalone
- Giovanni Guaraldi
- Chiara Mussi
- Andrea Calcagno
- Agostino Riva
- Giovanni Di Perri
- Emanuele Focà
- Paolo Bonfanti
- Paola Pignata
- Giuseppe Vittorio De Socio
- Samuele Gardini
- Micol Ferrara
- Andrea Piazzoli
- Tiziano Lucchi
- Claudio Mastroianni (ORCID: https://orcid.org/0000-0002-1286-467X)
- Federica Barrera
- for the GEPPO Study Group
- Stefania Arsuffi
- Marta Baroni
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Modena and Reggio Emilia (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Padua (IT)
- Vita-Salute San Raffaele University (IT)
- University of Sassari (IT)
- Agostino Gemelli University Polyclinic (IT)
- Brescia University (US)
- University of Catania (IT)
- Azienda Ospedaliera di Perugia (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Torino e-district (IT)
- Department of Medical Sciences (BY)
- Hospital for Tropical Diseases (VN)
- ASST Fatebenefratelli Sacco (IT)
- Piedmont University (US)
- University of Brescia (IT)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1093/ofid/ofaf817
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00